Table 2.
Linear regression models for central retinal venule equivalent (CRVE) and Framingham Reactive Hyperaemia Index (F-RHI) at 38, and logistic regression models for metabolic syndrome at 38.
| Central retinal venule equivalent (CRVE) at 38 | Framingham Reactive Hyperaemia Index (F-RHI) at 38 | Metabolic syndrome (MetS) at 38. | |
|---|---|---|---|
| Coefficient (95% CI) | Coefficient (95% CI) | Odds ratio (95% CI) | |
| Cross-sectional models | Model 1 | Model 3 | Model 5 |
| Inflammatory load at age 38 | 0.11 (-0.06, 0.29) | -0.00 (-0.01, 0.01) | 1.03 (0.99, 1.07) |
| CRAE at 38 | 0.89 (0.82, 0.96) | ||
| Male | 2.50 (0.99, 4.00) | -0.19 (-0.25, -0.14) | 1.63 (1.08, 2.48) |
| Low SES at 38 | 1.29 (-0.87, 3.44) | -0.02 (-0.09, 0.06) | 1.11 (0.64, 1.91) |
| Current smoker at 38 | 2.92 (1.08, 4.77) | -0.04 (-0.11, 0.02) | 0.98 (0.60, 1.58) |
| Dysglycaemia at 38 | 1.59 (-0.36, 3.54) | -0.04 (-0.11, 0.02) | 7.66 (5.03, 11.65) |
| High plaque score group at 38 | -0.00 (-3.13, 3.12) | -0.09 (-0.19, 0.02) | 0.95 (0.44, 2.01) |
| Longitudinal models | Model 2 | Model 4 | Model 6 |
| Change in inflammatory load 32–38 | -0.02 (-0.21, 0.17) | -0.00 (-0.01, 0.01) | 1.01 (0.96, 1.06) |
| CRAE at 38 | 0.89 (0.81, 0.96) | ||
| Male | 2.61 (1.07, 4.15) | -0.19 (-0.25, -0.14) | 1.55 (1.01, 2.36) |
| Low SES at 38 | 1.57 (-0.59, 3.73) | -0.02 (-0.09, 0.06) | 1.11 (0.64, 1.92) |
| Current smoker at 38 | 3.13 (1.28, 4.97) | -0.04 (-0.11, 0.02) | 1.05 (0.65, 1.70) |
| Dysglycaemia at 38 | 1.71 (-0.28, 3.70) | -0.04 (-0.11, 0.02) | 7.55 (4.93, 11.55) |
| High plaque score group at 38 | 0.50 (-2.68, 3.68) | -0.09 (-0.19, 0.02) | 1.04 (0.49, 2.24) |
Note that observations were lost when individuals had a missing observation for a variable. CI; Confidence interval. Statistically significant findings in bold type.
N = 836 for CRVE cross-sectional model, N = 808 for CRVE longitudinal model. N = 829 for F-RHI cross-sectional model, N = 802 for F-RHI longitudinal model.
N = 836 for MetS cross-sectional model, N = 808 for MetS longitudinal model.
Metabolic syndrome (MetS) categorised according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP, ATP III) criteria. Three individuals with Type 1 diabetes were excluded from the MetS analysis.
Reference categories: female (for male); high SES at 38 (for low SES at 38); not current smoker at 38 (for current smoker at 38); not dysglycaemic at 38 (for dysglycaemic at 38); low plaque score group at 38 (for high plaque score group at 38).